Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.

Baek IH, Lee BY, Kim MS, Kwon KI.

Eur J Drug Metab Pharmacokinet. 2013 Dec;38(4):295-9. doi: 10.1007/s13318-013-0130-4. Epub 2013 Apr 7.

PMID:
23564503
2.

[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].

Minami H, Ebi H.

Gan To Kagaku Ryoho. 2005 Dec;32(13):2053-7. Japanese.

PMID:
16352928
3.

Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.

Hamada A, Fukushima S, Morinaga A, Saneyoshi M, Kawaguchi T, Nakano M.

Biol Pharm Bull. 1993 Dec;16(12):1297-300.

PMID:
8130783
5.

Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.

Zampino MG, Colleoni M, Bajetta E, Stampino CG, Guenzi A, de Braud F.

Tumori. 1999 Jan-Feb;85(1):47-50.

PMID:
10228497
6.

Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.

Deng P, Ji C, Dai X, Zhong D, Ding L, Chen X.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:71-9. doi: 10.1016/j.jchromb.2015.03.002. Epub 2015 Mar 9.

PMID:
25808944
8.

Simultaneous determination of doxifluridine and 5-fluorouracil in monkey serum by high performance liquid chromatography with tandem mass spectrometry.

Woo YA, Kim GH, Jeong EJ, Kim CY.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):487-92. doi: 10.1016/j.jchromb.2008.09.037. Epub 2008 Oct 7.

PMID:
18945647
9.

Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.

Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M.

Pharmacol Res. 2004 Aug;50(2):173-9.

PMID:
15177306
10.

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Barberi-Heyob M, Weber B, Merlin JL, Dittrich C, de Bruijn EA, Luporsi E, Guillemin F.

Cancer Chemother Pharmacol. 1995;37(1-2):110-6.

PMID:
7497579
11.

Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.

Hamada A, Fukushima S, Saneyoshi M, Shimizu S, Kawaguchi T, Nakano M.

Biol Pharm Bull. 1996 May;19(5):729-32.

PMID:
8741584
13.

Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats.

Konishi H, Yoshimoto T, Morita K, Minouchi T, Sato T, Yamaji A.

J Pharm Pharmacol. 2003 Jan;55(1):143-9.

PMID:
12625878
15.

Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).

Ebi H, Sigeoka Y, Saeki T, Kawada K, Igarashi T, Usubuchi N, Ueda R, Sasaki Y, Minami H.

Cancer Chemother Pharmacol. 2005 Aug;56(2):205-11. Epub 2005 Apr 21.

PMID:
15844007
16.

Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.

Ozawa S, Hamada M, Murayama N, Nakajima Y, Kaniwa N, Matsumoto Y, Fukuoka M, Sawada J, Ohno Y.

Cancer Chemother Pharmacol. 2002 Dec;50(6):454-8. Epub 2002 Oct 26.

PMID:
12451471
17.

Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Au JL, Wientjes MG, Bramer SL.

Cancer Chemother Pharmacol. 1988;22(1):5-10.

PMID:
2969304
18.
19.
20.

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.

Bajetta E, Di Bartolomeo M, Somma L, Del Vecchio M, Artale S, Zunino F, Bignami P, Magnani E, Buzzoni R.

Eur J Cancer. 1997 Apr;33(4):687-90.

PMID:
9274455

Supplemental Content

Support Center